Table 4 Bivariate analysis of risk factors for flares and irAEs
No flares n (%) | Flares n (%) | OR (exact 95% CI) | No irAEs n (%) | irAEs n (%) | OR (exact 95% CI) | |
|---|---|---|---|---|---|---|
Rheumatologic disease | ||||||
Other (n = 23) | 20 (87) | 3 (13) | Reference | 12 (52) | 11 (48) | Reference |
RA (n = 22) | 12 (55) | 10 (45) | 5.34 (1.09–36.3) | 13 (59) | 9 (41) | 0.76 (0.20–2.86) |
Age | ||||||
< 65 (n = 17) | 12 (71) | 5 (29) | Reference | 12 (71) | 5 (29) | Reference |
≥ 65 (n = 28) | 20 (71) | 8 (29) | 0.96 (0.21–4.65) | 13 (46) | 15 (54) | 2.71 (0.66–12.6) |
Gender | ||||||
Female (n = 31) | 21 (68) | 10 (32) | Reference | 16 (52 | 15 (48) | Reference |
Male (n = 14) | 11 (79) | 3 (21) | 0.58 (0.08–2.93) | 9 (64) | 5 (36) | 0.60 (0.13–2.56) |
Rheumatologic treatment | ||||||
No (n = 23) | 16 (70) | 7 (30) | Reference | 16 (70) | 7 (30) | Reference |
Yes (n = 22) | 16 (73) | 6 (27) | 0.86 (0.19–3.76) | 9 (41) | 13 (59) | 3.21 (0.83–13.6) |
Autoimune disease control before ICI therapy | ||||||
No (n = 5) | 4 (80) | 1 (20) | Reference | 1 (20) | 4 (80) | Reference |
Yes (n = 40) | 28 (70) | 12 (30) | 1.70 (0.15–91.4) | 24 (60) | 16 (40) | 0.17 (0.00–1.96) |